✦ LIBER ✦

EU to review rare disease drugs market exclusivity

✍ Scribed by Sheridan, Cormac

Book ID: 109907297
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 151 KB
Volume: 22
Category: Article
ISSN: 1087-0156
DOI: 10.1038/nbt0904-1061

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug discovery market exclusivity after

Drug discovery market exclusivity after KSR:The challenge to pharmaceutical scientists and the US congress

✍ Manfred E. Wolff 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Adult-onset Still's disease: a concise r

Adult-onset Still's disease: a concise review of clues to an important rare syndrome

✍ SCHACHNA, L. ;LITTLEJOHN, G. O. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Priority Review Vouchers: An Inefficient

Priority Review Vouchers: An Inefficient and Dangerous Way to Promote Neglected-Disease Drug Development

✍ Kesselheim, AS 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 99 KB

The Impact of the Orphan Drug Act on the

The Impact of the Orphan Drug Act on the Development and Advancement of Neurological Products for Rare Diseases: A Descriptive Review

✍ Burke, K A; Freeman, S N; Imoisili, M A; Coté, T R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 105 KB

Cost-effectiveness of biologic response

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

✍ Gabrielle van der Velde; Ba' Pham; Márcio Machado; Luciano Ieraci; William Witte 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 172 KB 👁 2 views

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4